Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27642437 | 0.92 | KDM4C (0.54) | KDM4CSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL331623 | 0.92 | KDM4C (0.61) | KDM4CSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL331274 | 0.84 | ALDH1A1 (0.36) | KDM4CSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL14441199 | 0.82 | KDM4C (0.50) | KDM4CSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL1558734 | 0.80 | KDM4C (0.50) | KDM4CSMN1; SMN2ALDH1A1KDM4ESTAT3 | |
| SCHEMBL29157189 | 0.79 | KDM4E (0.38) | KDM4CALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL31616846 | 0.77 | KDM4C (0.47) | KDM4CSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL2911328 | 0.76 | KDM4C (0.46) | KDM4CSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL16919030 | 0.76 | KDM4C (0.62) | KDM4CSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL11340041 | 0.76 | MAPT (0.42) | ALDH1A1KDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109627235-B | High-energy insensitive energetic compound and synthesis method thereof | 南京理工大学 | 2020-12-04 | — | — | CN | disclosed |
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20080194591-A1 | Phosphodiesterase inhibitor | PFIZER INC. | 2008-08-14 | — | — | US | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| CN-1780841-A | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the traetment of hypertension | PFIZER LTD (GB) | 2006-05-31 | — | — | CN | disclosed |
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-6831074-B2 | Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders | PFIZER INC | 2004-12-14 | — | — | US | disclosed |
| EP-1123296-B1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-1241170-A2 | Pyrazolopyrimidine derivatives | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6333330-B1 | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-12-25 | — | — | US | disclosed |
| EP-1123296-A1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024745-A1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194591-A1 | Phosphodiesterase inhibitor | PDE5A, PDE3B, PDE3A | KDM4C 369/4885SMN1; SMN2 2071/4885ALDH1A1 696/4885 |
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | KDM4C 3970/4885SMN1; SMN2 2626/4885ALDH1A1 851/4885 |
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | KDM4C 2119/4885SMN1; SMN2 2441/4885ALDH1A1 720/4885 |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | KDM4C 3970/4885SMN1; SMN2 2626/4885ALDH1A1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.